Latest Anakinra Stories
THOUSAND OAKS, Calif., and COLLEGEVILLE, Pa., Nov. 6, 2010 /PRNewswire/ -- Amgen Inc. (Nasdaq: AMGN), Pfizer Inc.
ATLANTA, Oct. 15 /PRNewswire/ -- Studies and analyses of the Crohn's disease (CD) treatment CimziaÂ® (certolizumab pegol) will be exhibited at the 2010 Annual Scientific Meeting of the American College of Gastroenterology, taking place in San Antonio from October 15 - 20.
A study conducted at Copenhagen University Hospital showed that treatment of rheumatoid arthritis (RA) with disease modifying antirheumatic drugs (DMARDs), glucocorticoids, biologic agents, or a combination of agents significantly reduced radiographic evidence of joint destruction, with a relative effect of 48%óˆž´% as compared with placebo.
HORSHAM, Pa., Sept. 27 /PRNewswire/ -- Centocor Ortho Biotech Inc. announced today that it has submitted a supplemental Biologics License Application (sBLA) to the U.S.
The Food and Drug Administration (FDA) received reports of malignancies in children using tumor necrosis factor a (TNF) blockers, raising concerns of an associated risk and prompting an investigation.
ATLANTA, June 16 /PRNewswire-FirstCall/ -- UCB today announced new CimziaÂ® (certolizumab pegol) data demonstrating rapid and sustained improvements in managing moderate to severe rheumatoid arthritis (RA) symptoms and pain for patients, as well as results of a survey showing the impact of RA pain on the daily lives of women, focusing on productivity and relationships, during the 2010 European League Against Rheumatism (EULAR) annual congress in Rome, Italy, June 16-19. "Insights from these...
NORTHBROOK, Ill., June 16 /PRNewswire/ -- Horizon Pharma, Inc., announced today that data from the Phase 3 U.S.
ATLANTA, May 2 /PRNewswire/ -- UCB announced today results of an open-label extension study, PRECiSE 4 (P4), of CimziaÂ® (certolizumab pegol; CZP) demonstrating that Cimzia provides sustained efficacy over four years in moderate to severe Crohn's Disease patients regardless of whether patients were previously treated with infliximab (IFX) or infliximab-naive.
- The act of sweetening by admixture of some saccharine substance.